Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Immunovia AB ( (SE:IMMNOV) ) has provided an update.
Immunovia AB held an extraordinary general meeting on September 29, 2025, where resolutions were adopted to amend the Articles of Association and approve a rights issue of shares. This rights issue aims to raise approximately SEK 100 million, enhancing the company’s financial position and enabling strategic initiatives. Additionally, the board was authorized to issue shares to guarantors, ensuring the successful execution of the rights issue, which could impact the company’s market operations and stakeholder interests.
More about Immunovia AB
Immunovia AB is a diagnostic company dedicated to increasing survival rates for pancreatic cancer patients through early detection. The company focuses on developing and commercializing blood-based tests to detect proteins and antibodies indicative of pancreatic cancer, collaborating with healthcare providers, experts, and advocacy groups to serve high-risk individuals, particularly in the USA, its largest market.
YTD Price Performance: -13.19%
Average Trading Volume: 11,015,996
Technical Sentiment Signal: Sell
Current Market Cap: SEK145.1M
Learn more about IMMNOV stock on TipRanks’ Stock Analysis page.